Because NV556 and CRV431 inhibit all cyclophilins, it is unknown whether inhibition of a specific family member is the most responsible for the previously observed beneficial effects in the context of NAFLD/NASH and the development of HCC. Here, PPIB is linked to metabolic dysfunction-associated steatotic liver disease.